NHS Gives Green Light to Life-Changing SMA Treatments
NICE has recommended routine NHS access to nusinersen and risdiplam for spinal muscular atrophy.
Market Access
EU Critical Medicines Act Fights Dangerous Supply Crisis
The EU’s Critical Medicines Act takes direct aim at the supply chain vulnerabilities that leave patients without essential drugs when it matters most.
NICE backs digital asthma tools for NHS use as evidence builds
The UK health watchdog National Institute for Health and Care Excellence (NICE) has recommended a suite of digital platforms to help people with asthma better manage their condition, signalling growing confidence in app-based tools as part of routine care, while stopping short of full endorsement pending further evidence. In draft guidance published yesterday, NICE said … Read more
IQWiG Highlights Evidence Gaps Despite Growing Treatment Options
Last week’s policy signals from Germany underscored a clear regulatory theme: access increasingly hinges on comparative evidence, not just innovation or unmet need. New assessments from the Institute for Quality and Efficiency in Health Care (IQWiG) highlighted where evidence is strong enough to support added benefit, where gaps remain despite growing treatment options. Multiple myeloma: … Read more
NICE Backs Age-Based Blood Test to Spot Ovarian Cancer
NICE proposes age-based CA125 testing to improve early diagnosis.
Germany Updates Meningococcal, Shingles Vaccine Policy for 2026
Germany adopts new STIKO vaccination recommendations, shifting meningococcal protection to adolescents and expanding shingles eligibility for high-risk adults starting in 2026.
EU Finalizes Landmark Pharma Reform to Reset Access and Incentives
The EU reaches a landmark deal on pharmaceutical reform, reshaping regulatory exclusivity, supply obligations, generic entry, and incentives for priority antibiotics.
CMS Confirms 2026 Coverage for MTF’s AmnioBand, AlloPatch
CMS confirms Medicare coverage for MTF Biologics’ AmnioBand Membrane and AlloPatch Pliable under updated LCDs for diabetic foot and venous leg ulcers starting 2026.
Netherlands Moves to Cut Mental Health Wait Times for 2026
The Dutch Healthcare Institute prioritizes group therapy and preventive mental health care to reduce long wait times under its 2026–2028 appropriate care agenda.
BioStem Lands 2026 CMS Status Quo Coverage for Skin Grafts
CMS places BioStem’s VENDAJE products in a 12-month status quo category, preserving DFU and VLU reimbursement through 2026 while evidence review continues.